These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 12216303)

  • 1. Limited vision.
    Sadler C
    Nurs Stand; 2002 Jul 3-9; 16(42):14-5. PubMed ID: 12216303
    [No Abstract]   [Full Text] [Related]  

  • 2. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.
    Bansback N; Davis S; Brazier J
    Eye (Lond); 2007 Dec; 21(12):1455-63. PubMed ID: 17086167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case.
    Smith DH; Fenn P; Drummond M
    Br J Ophthalmol; 2004 Sep; 88(9):1107-12. PubMed ID: 15317697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combating blindness.
    Evans J
    Practitioner; 2002 Jul; 246(1636):467. PubMed ID: 12132263
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation.
    Meads C; Salas C; Roberts T; Moore D; Fry-Smith A; Hyde C
    Health Technol Assess; 2003; 7(9):v-vi, 1-98. PubMed ID: 12709292
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.
    Hopley C; Salkeld G; Mitchell P
    Br J Ophthalmol; 2004 Aug; 88(8):982-7. PubMed ID: 15258009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatments for age-related macular degeneration.
    Wagle AM; Yeo TK; Au Eong KG
    Lancet; 2007 Oct; 370(9597):1481. PubMed ID: 17964347
    [No Abstract]   [Full Text] [Related]  

  • 8. Can [symbol: see text] verteporfin help in macular degeneration?
    Drug Ther Bull; 2001 Apr; 39(4):30-2. PubMed ID: 11329798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of photodynamic therapy with verteporfin.
    Lees MJ; Aldridge GJ; Davey PJ; Gorgievski M
    Ophthalmology; 2003 Apr; 110(4):626-7; author reply 627-8. PubMed ID: 12689865
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy.
    Greiner RA
    Semin Ophthalmol; 2001 Dec; 16(4):218-22. PubMed ID: 15513444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sight-saving treatments for age-related macular degeneration. New drugs offer new hope for managing a leading cause of blindness.
    Johns Hopkins Med Lett Health After 50; 2012; 24(12):1-4. PubMed ID: 23757782
    [No Abstract]   [Full Text] [Related]  

  • 12. [Photodynamic therapy in age-related macular degeneration].
    Seres A; Papp A; Süveges I
    Orv Hetil; 2005 Oct; 146(42):2143-9. PubMed ID: 16315995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A limited free eye test?
    Harrison R
    Practitioner; 1997 Apr; 241(1573):171. PubMed ID: 9206285
    [No Abstract]   [Full Text] [Related]  

  • 14. US report draws attention to preventable vision problems.
    Senior K
    Lancet; 2002 Mar; 359(9312):1129. PubMed ID: 11943270
    [No Abstract]   [Full Text] [Related]  

  • 15. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC; Lade RJ; Adewoyin T; Chong NV
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age-related macular degeneration.
    Larsson J; Gillies MC
    Clin Exp Ophthalmol; 2005 Oct; 33(5):544-5. PubMed ID: 16181292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR; Moride Y; Rochon S
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost of vision for vitreoretinal interventions.
    Smiddy WE
    Curr Opin Ophthalmol; 2008 May; 19(3):195-201. PubMed ID: 18408493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of treatment of age-related macular degeneration: a review.
    Kymes Steven M
    Minerva Med; 2009 Feb; 100(1):69-78. PubMed ID: 19277005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatments for age-related macular degeneration.
    Hamilton WS
    Lancet; 2007 Oct; 370(9597):1480-1. PubMed ID: 17964344
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.